Evidence map›Paper›PMID 27502548›Full record

ReviewNature reviews. Urology2016

Contemporary evidence for robot-assisted radical cystectomy for treating bladder cancer.

Raj Satkunasivam, Christopher J D Wallis, Robert K Nam, Mihir Desai, Inderbir S Gill

Open access · greenAbstract readReview
In one paragraph

Review in Nature reviews. Urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Robotic assistance helps low-volume surgeons deliver better outcomes to their patients.Indian journal of urology : IJU : journal of the Urological Society of India
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Raj SatkunasivamDivision of Urology, Department of Surgery, Sunnybrook Health Sciences Centre and University of Toronto, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada.
Christopher J D WallisDivision of Urology, Department of Surgery, Sunnybrook Health Sciences Centre and University of Toronto, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada.
Robert K NamDivision of Urology, Department of Surgery, Sunnybrook Health Sciences Centre and University of Toronto, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada.
Mihir DesaiUSC Institute of Urology and Norris Comprehensive Cancer Center, Keck School of Medicine of USC, University of Southern California, 1441 Eastlake Avenue, Los Angeles, California 90033, USA.
Inderbir S GillUSC Institute of Urology and Norris Comprehensive Cancer Center, Keck School of Medicine of USC, University of Southern California, 1441 Eastlake Avenue, Los Angeles, California 90033, USA.
Health Sciences Centre · CAUniversity of Southern California · USUniversity of Toronto · CA

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
NCI NIH HHS P30 CA014089
6 · The paper itself

Abstract

Robot-assisted radical cystectomy (RARC) is an evolving technique for the treatment of muscle-invasive bladder cancer (MIBC); however, its effectiveness compared with open radical cystectomy (ORC) - the established modality - is debated. Six specific areas of evidence are critically important for supporting the continuing use of RARC for MIBC, including technical aspects of surgery, perioperative outcomes, complications, oncological outcomes, functional outcomes, and financial costs. Considerable progress has been made regarding these aspects and data show that RARC replicates the technical benchmarks of ORC in terms of success of cystectomy, lymph node dissection, and urinary diversion, and could offer advantages over the more-established technique. Despite some clear benefits of RARC (such as reduced blood loss) other perioperative outcomes, including duration of inpatient stay and 30-90 day complication rates, seem to be similar to those of ORC. Current data on oncological and functional outcomes are promising, but robust data from prospective studies will help determine the indications for use of RARC for treating MIBC in the future.

Indexed as

Cost-Benefit AnalysisCystectomyEvidence-Based MedicineHumansRandomized Controlled Trials as TopicRobotic Surgical ProceduresTreatment OutcomeUrinary Bladder Neoplasms

Identifiers

PMID27502548
PMCPMC9084475
OpenAlexW2479289770

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.